Systematic versus Perilesional sampling in Transperineal MRI-Fusion Biopsy: Is Perilesional Sampling Ready for Prime Time? A Real-World High-Volume Center Analysis

Systematic versus Perilesional sampling in Transperineal MRI-Fusion Biopsy: Is Perilesional Sampling Ready for Prime Time? A Real-World High-Volume Center Analysis - SYSVSPERI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039137

Enrollment

314

Registered

2026-02-23

Start date

2026-02-11

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: A retrospective analysis was performed on all patients who underwent a fusion biopsy of the prostate with a PI-RADS 3, 4 or 5 finding.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: PI-RADS 3,4 or 5 lesion in MRI biopsy-naive

Exclusion criteria

Exclusion criteria: PI-RADS 1 or 2 in MRI not biopsy-naive

Design outcomes

Primary

Measure	Time frame
Detection rate of clinically significant prostate cancers (defined as prostate cancer with an ISUP = 2) retrospective data collection from existing data from routine clinical examinations	—

Countries

Germany

Contacts

Public ContactAgneta Seebold

Klinik und Poliklinik für Urologie und Kinderurologie der Universitätsklinik Bonn

Agneta.Seebold@ukbonn.de+4915208461493

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026